Compare Ginkgo Bioworks Holdings Inc (DNA) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs ProShares UltraPro S&P500 — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.94 (market cap $763.64M), while ProShares UltraPro S&P500 trades at $155.83 (market cap $5.55B). The key difference: ProShares UltraPro S&P500 is far larger — about 7.3× Ginkgo Bioworks Holdings Inc's market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and ProShares UltraPro S&P500 for 29 Days on average.
| DNA | UPRO | |
|---|---|---|
Market Cap | $763.64M | $5.55B |
Volume | 3,204,177 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $15.83 | $157.66 |
52-Week Low | $5.48 | $89.29 |
Typical Hold Time | 7 Days | 29 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
UPRO trades at $155.78, up 0.37% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces resistance near $157 and support at $151. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. A dividend of $0.27 is scheduled for September 2026, indicating potential income for investors.
The outlook for UPRO is mixed, with technical strength offset by limited fundamental visibility. Risks include market volatility and concentration in top S&P 500 holdings. Upside depends on broader index performance, but investor skepticism amid high valuations may cap gains. Monitoring earnings growth and institutional sentiment is critical for direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
